Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma.

Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJ.

Haematologica. 2014 Sep;99(9):e162-4. doi: 10.3324/haematol.2014.110395. Epub 2014 Jun 27. No abstract available.

2.

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Nordgren B, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R.

Blood. 2012 Aug 30;120(9):1801-9. doi: 10.1182/blood-2012-04-422683. Epub 2012 Jun 4.

3.

Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy.

Sinha S, Lacy M, Mikhael J, Hayman S, Buadi F, Detweiler-Short K, Dispenzieri A, Gertz M, Dingli D, Rajkumar SV, Kumar SK.

Leukemia. 2012 Apr;26(4):839-41. doi: 10.1038/leu.2011.279. Epub 2011 Oct 11. No abstract available.

PMID:
21986842
4.

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.

Madan S, Lacy MQ, Dispenzieri A, Gertz MA, Buadi F, Hayman SR, Detweiler-Short K, Dingli D, Zeldenrust S, Lust J, Greipp PR, Rajkumar SV, Kumar S.

Blood. 2011 Aug 18;118(7):1763-5. doi: 10.1182/blood-2011-04-350009. Epub 2011 Jun 14.

5.

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.

Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S, Buadi F, Zeldenrust S, Leung N, Detweiler-Short K, Lust JA, Russell SJ, Kyle RA, Gertz MA.

Am J Hematol. 2010 Oct;85(10):757-9. doi: 10.1002/ajh.21822.

6.

Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma.

Detweiler-Short K, Hayman S, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Zeldenrust SR, Russell SJ, Lust JA, Kyle RA, Greipp PR, Witzig TE, Vincent Rajkumar S.

Am J Hematol. 2010 Oct;85(10):737-40. doi: 10.1002/ajh.21821.

Supplemental Content

Loading ...
Support Center